Scholar Rock Holding Corporation
HealthcareNASDAQ:SRRK · NASDAQ Global Select
-$0.24 today
Vol 1.15M · Avg 1.45M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-154.0%
avg -44.7%
ROIC
-108.5%
avg -50.6%
ROA
-93.5%
avg -44.5%
Analysis
ROA is currently the strongest return metric at -93.5% versus its period average of -44.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David L. Hallal | Chief Executive Officer & Chairman of the Board | $3.16M | — | 60 | $1.64M | 1.37% |
Akshay Krishnadas Vaishnaw | President of R&D, Member of Scientific Advisory Board and Director | $2.83M | — | 63 | $630,542.00 | 0.53% |
Akshay K. Vaishnaw | President of R&D, Member of Scientific Advisory Board and Director | $2.83M | — | 63 | $630,542.00 | 0.53% |
Robert Keith Woods | Chief Operating Officer | $1.11M | — | 58 | $620,055.00 | 0.52% |
Vikas Sinha | CFO & Treasurer | $1.06M | — | 63 | $619,856.00 | 0.52% |
Jing L. Marantz | Chief Medical Officer | $755,185.00 | — | 61 | $126,012.00 | 0.11% |
Mo Qatanani | Chief Scientific Officer | $704,681.00 | — | 53 | $99,502.00 | 0.08% |
Junlin | General Counsel & Corporate Secretary | $563,729.00 | — | 47 | $241,545.00 | 0.20% |
Caryn Parlavecchio | Chief Human Resources Officer | — | — | 54 | $169,087.00 | 0.14% |
Erin Moore | Interim Principal Financial & Accounting Officer | — | — | 51 | $96,173.00 | 0.08% |
Lisa Amaya Price | Senior Vice President of Human Resources | — | — | — | — | — |
Lisa Wyman | Chief Technical & Quality Officer | — | — | 48 | — | — |
Rebecca McLeod | Chief Brand Officer & GM of U.S. | — | — | — | — | — |
Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations | — | — | — | — | — |
Ryan Iarrobino | Senior Vice President of Clinical Development & Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$19.99M
Sells
40
$21.78M
Net Sentiment
$1.79M
Net selling
Most Active
Qatanani Mo
13 transactions
1–10 of 49
Analysis
Insiders reported 9 buys worth $19.99M and 40 sells worth $21.78M over the last 12 months. That adds up to net selling of $1.79M. Qatanani Mo was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +49.1% (10yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +49.1% (10yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.72B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.12B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.91B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.56B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Who manages SRRK?
Scholar Rock Holding Corporation (SRRK) lists 15 active executives. The top listed executive is Jing L. Marantz, Chief Medical Officer.
Are SRRK insiders buying or selling?
Recent insider activity shows net buying of $27.29M.
Explore More
Continue the stock analysis
Jump to another research area for this company.